Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859335 | 0.92 | TBXAS1 (0.45) | TBXAS1CYP11B1CYP11B2MKNK1MKNK2 | |
| SCHEMBL5860209 | 0.89 | PTPN1 (0.42) | CYP2C9KDM4ELMNAHTTALDH1A1 | |
| SCHEMBL5859180 | 0.85 | CYP2C9 (0.43) | TBXAS1CYP11B1CYP11B2CYP19A1CYP2C9 | |
| SCHEMBL5859125 | 0.84 | PSMD14 (0.49) | CYP11B1CYP11B2KDM4ELMNAALDH1A1 | |
| SCHEMBL5859030 | 0.83 | HTT (0.42) | TBXAS1CYP11B1CYP11B2CYP2C9KDM4E | |
| SCHEMBL5859178 | 0.81 | MAPT (0.48) | LMNA | |
| SCHEMBL5859000 | 0.81 | CYP46A1 (0.42) | TBXAS1CYP19A1CYP2C9LMNAHTT | |
| SCHEMBL5859203 | 0.80 | FOLH1 (0.51) | CYP2C9KDM4ELMNAHTTALDH1A1 | |
| SCHEMBL6097833 | 0.80 | LRRK2 (0.45) | TBXAS1LMNAHSD17B10DHODH | |
| SCHEMBL5859338 | 0.80 | TBXAS1 (0.43) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122543-B2 | Substituted benzoic acid derivatives having NF-κB inhibiting action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| EP-1437339-A1 | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | NFKBIA, NFKB2, IKBKB | TBXAS1 563/4885CYP11B1 429/4885CYP11B2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.